Immune globulin - Grifols

Drug Profile

Immune globulin - Grifols

Alternative Names: Flebogamma 10% DIF; Flebogamma 5% DIF; Flebogamma DIF; IGSC 20% - Grifols; Intravenous normal Human immunoglobulin – Grifols; IVIG - Grifols; Xepol; XS-28

Latest Information Update: 26 May 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Grifols
  • Class Immunoglobulins; Immunoproteins; Serum globulins
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Postpoliomyelitis syndrome
  • New Molecular Entity No

Highest Development Phases

  • Marketed Guillain-Barre syndrome; Idiopathic thrombocytopenic purpura; Immunodeficiency disorders
  • Registered Mucocutaneous lymph node syndrome
  • Phase III Alzheimer's disease
  • Phase II/III Postpoliomyelitis syndrome

Most Recent Events

  • 12 May 2016 Phase-III clinical trials in Immunodeficiency disorders (In children, In adults, In adolescents) in United Kingdom, Spain (SC) (EudraCT2015-003290-15)
  • 18 Nov 2015 Grifols Therapeutics plans a phase III trial for Immunodeficiency disorders (In children, In adolescents, In adults) USA (SC) (NCT02604810)
  • 31 Mar 2015 Phase-III development for Alzheimer's disease is ongoing in USA and Spain
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top